Clinical Trials on Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation

Total 82 results

Yonsei University

Unknown

Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study

Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation

Korea, Republic of
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Multiple Myeloma | Newly Diagnosed Multiple Myeloma | Autologous Stem Cell Transplantation

United States
Chen Wenming
307 Hospital of PLA

Unknown

Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients

Multiple Myeloma in Relapse | Autologous Stem Cell Transplantation | Microtransplantation

China
PETHEMA Foundation
Janssen, LP; Adknoma Health Research

Recruiting

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Multiple Myeloma | Non-eligible for Autologous Stem Cell Transplantation (ASCT)

Spain
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients. (DILEMMA)

Multiple Myeloma | Daratumumab | Autologous Stem Cell Transplantation | Leukapheresis

Italy
Nanfang Hospital of Southern Medical University
Guangzhou First People's Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen... and other collaborators

Unknown

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Multiple Myeloma | Conditioning | Autologous Hematopoietic Stem Cell Transplantation

China
University Hospital Inselspital, Berne

Completed

Pedometer Activity Monitoring After ASCT (PAMAL)

Lymphoma | Myeloma | Autologous Stem Cell Transplantation | High-dose Chemotherapy

Switzerland
Jacob Laubach, MD
Sanofi

Active, not recruiting

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Multiple Myeloma | Autologous Stem Cell Transplant | Newly Diagnosed Multiple Myeloma (NDMM)

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Completed

TARC After alloSCT in Hodgkin's Lymphoma (TARC)

Hodgkin's Lymphoma Patients Who Underwent an Allogeneic Stem Cell Transplantation

Italy
Hospital Clinic of Barcelona
Instituto de Salud Carlos III; European Union

Completed

Prevention of Left Ventricular Dysfunction During Chemotherapy (OVERCOME)

Lymphoma | Acute Myeloid Leukemia | Multiple Myeloma | Lymphoid Neoplasm | Autologous Hematopoietic Stem Cell Transplantation | Precursor-cell Lymphoblastic Leukemia-Lymphoma

Spain
Takeda

Active, not recruiting

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

Multiple Myeloma | Autologous Stem Cell Transplant

United States, Spain, Australia, Czechia, Hungary, Taiwan, Italy, Denmark, Portugal, Singapore, Israel, Canada, France, Belgium, United Kingdom, Germany, Japan, Austria, Netherlands, Korea, Republic of, Poland, Greece, Colombia, Sweden, South Africa and more
Sanofi

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients

Autologous Haematopoietic Stem Cell Transplant

China
M.D. Anderson Cancer Center

Completed

Lenalidomide and High-Dose Melphalan

Stem Cell Transplantation | Myeloma

United States
Mayo Clinic

Recruiting

Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma Patients

Multiple Myeloma | Autologous Stem Cell Transplant

United States
Genzyme, a Sanofi Company

Completed

Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).

Multiple Myeloma | Autologous Transplantation
Stanford University

Completed

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Multiple Myeloma | Blood and Marrow Transplant (BMT) | Transplantation, Autologous | Transplantation, Homologous

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia | Loss of Chromosome 17p | Autologous Hematopoietic Stem Cell Transplant Recipient

United States
Fundación Pública Andaluza para la gestión de la...

Not yet recruiting

Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant (CARTemis-1)

Multiple Myeloma | Allogeneic Stem Cell Transplantation

Spain
Universitätsklinikum Hamburg-Eppendorf

Completed

Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma

Multiple Myeloma | Stem Cell Transplantation
M.D. Anderson Cancer Center
CTI BioPharma

Completed

Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients

Multiple Myeloma | Stem Cell Transplantation

United States
University of Maryland, Baltimore
Healogics

Withdrawn

Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers

Lymphoma | Multiple Myeloma | Bone Marrow Transplantation | Hematopoietic Stem Cells

United States
Charite University, Berlin, Germany
University of Leipzig

Unknown

Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells

Acute Myeloid Leukemias | Advanced Hematological Malignancies | Indication for Allogeneic Stem Cell Transplantation | no HLA-identical Donor Available

Germany
Federal University of Health Science of Porto Alegre

Unknown

Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation

Lymphoma | Leukemia | Fatigue | Multiple Myeloma | Hematopoietic Stem Cell Transplantation

Brazil
National Heart, Lung, and Blood Institute (NHLBI)
Blood and Marrow Transplant Clinical Trials Network

Completed

Blood and Marrow Transplant Clinical Research Network

Myelodysplastic Syndromes | Leukemia | Multiple Myeloma | Blood Disease | Bone Marrow Transplantation | Hematopoietic Stem Cell Transplantation | Graft vs Host Disease

United States
University Hospital, Montpellier
Poitiers University Hospital

Unknown

Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment

Patients With Recurrent or Refractory Multiple Myeloma

France
University of Heidelberg Medical Center
German Cancer Research Center; University Hospital Heidelberg; Array BioPharma; Coordinating Centre for Clinical Trials Heidelberg

Active, not recruiting

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) (GMMG-BIRMA)

Relapsed or Refractory Multiple Myeloma | Patients With BRAFV600 E or BRAFV600K Mutation

Germany
Institute of Hematology & Blood Diseases Hospital

Recruiting

National Longitudinal Cohort of Hematological Diseases (NICHE)

Lymphoma | Acute Myeloid Leukemia | Leukemia | Hemophilia A | Hemophilia B | Hemophilia | Multiple Myeloma | Myelodysplastic Syndrome | Bone Marrow Transplantation | MDS | Aplastic Anemia | Bleeding Disorder | Myeloma, Multiple | Myelomas, Multiple | Leukemias, Acute Myeloid | Myeloid Leukemias, Acute | Hemophilia As | Hemophilia... and other conditions

China
Innate Pharma

Completed

Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse (KIRIMID)

Patients With Multiple Myeloma Experiencing a | First or Second Relapse

United States
Roswell Park Cancer Institute
Pfizer

Withdrawn

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 Positive | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Blasts 5 Percent or More of Peripheral Blood White Cells | Lymphoblasts... and other conditions

United States
Genzyme, a Sanofi Company

Completed

A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). (PREDICT)

Transplantation | Lymphoma (Non-Hodgkin's Lymphoma) | Hodgkin's Disease or Multiple Myeloma | Front Line Mobilization

Netherlands, France, Germany, Sweden, Spain, Italy, United Kingdom
Children's Hospital Los Angeles
Lucile Packard Children's Hospital

Terminated

Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells

Metabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
Autolus Limited

Enrolling by invitation

Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified

Multiple Myeloma | DLBCL | T Cell Lymphoma | Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy | ALL, Adult and Pediatric

United Kingdom
Novartis Pharmaceuticals

Completed

Post Hematopoietic Stem Cell Transplantation

Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major

Turkey
Fundación Pública Andaluza para la gestión de la...

Active, not recruiting

Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

Multiple Myeloma | Hematopoietic Stem Cell Transplantation

Spain
Celldex Therapeutics

Terminated

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs

Chronic Lymphocytic Leukemia (CLL) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Chronic Myelogenous Leukemia (CML) | Non-Hodgkins Lymphoma (NHL) | For Donors | Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling | For Recipients and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic-Myeloproliferative Diseases | Neuroblastoma | Infection | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Therapy-related Toxicity

United States
Fred Hutchinson Cancer Center

Active, not recruiting

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Myasthenia Gravis | Neuromyelitis Optica | Autoimmune Disease | Chronic Inflammatory Demyelinating Polyneuropathy | Lambert Eaton Myasthenic Syndrome | Cerebellar Degeneration | Stiff Person Syndrome | Opsoclonus Myoclonus Syndrome | Neurologic Autoimmune Disease | Autologous Transplant Autoimmune | Multiple... and other conditions

United States
UNC Lineberger Comprehensive Cancer Center

Recruiting

Registry for Adults With Plasma Cell Disorders (PCD's)

Multiple Myeloma | Amyloidosis | Smoldering Multiple Myeloma | Plasma Cell Leukemia | Cryoglobulinemia | Light Chain Deposition Disease | Castleman's Disease | Heavy Chain Deposition Disease | Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes

United States
Vanderbilt University
National Cancer Institute (NCI)

Terminated

Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Chronic Myeloproliferative Disorders | Cancer Survivor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Completed

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

Sarcoma | Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Neutropenia | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome

Lymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Indiana University School of Medicine
National Cancer Institute (NCI)

Completed

Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors

Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Cancer Treatment Centers of America

Completed

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

Sarcoma | Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Peking University First Hospital

Recruiting

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

Multiple Myeloma | Amyloidosis | Smoldering Multiple Myeloma | Plasma Cell Leukemia | Cryoglobulinemia | Light Chain Deposition Disease | Castleman's Disease | Heavy Chain Deposition Disease | Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes | Monoclonal Gammopathy of Undetermined... and other conditions

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult... and other conditions

United States, Germany, Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
National Cancer Institute (NCI)

Completed

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma and other conditions

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms | Nausea and Vomiting

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation

Sarcoma | Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Blood Samples From Patients on a Clinical Trial to CINV During HSCT

Lymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms | Nausea and Vomiting

United States

Clinical Trials on Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations